172 related articles for article (PubMed ID: 21818755)
1. Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
Courtney AN; Thapa P; Singh S; Wishahy AM; Zhou D; Sastry J
Eur J Immunol; 2011 Nov; 41(11):3312-22. PubMed ID: 21818755
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.
Thapa P; Zhang G; Xia C; Gelbard A; Overwijk WW; Liu C; Hwu P; Chang DZ; Courtney A; Sastry JK; Wang PG; Li C; Zhou D
Vaccine; 2009 May; 27(25-26):3484-8. PubMed ID: 19200815
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.
Kamijuku H; Nagata Y; Jiang X; Ichinohe T; Tashiro T; Mori K; Taniguchi M; Hase K; Ohno H; Shimaoka T; Yonehara S; Odagiri T; Tashiro M; Sata T; Hasegawa H; Seino KI
Mucosal Immunol; 2008 May; 1(3):208-18. PubMed ID: 19079180
[TBL] [Abstract][Full Text] [Related]
4. In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide.
Fernandez CS; Jegaskanda S; Godfrey DI; Kent SJ
Clin Exp Immunol; 2013 Sep; 173(3):480-92. PubMed ID: 23656283
[TBL] [Abstract][Full Text] [Related]
5. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY
Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581
[TBL] [Abstract][Full Text] [Related]
6. α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.
Chuang YH; Wang TC; Jen HY; Yu AL; Chiang BL
J Immunol; 2011 Apr; 186(8):4687-92. PubMed ID: 21383248
[TBL] [Abstract][Full Text] [Related]
7. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
Lindqvist M; Persson J; Thörn K; Harandi AM
J Immunol; 2009 May; 182(10):6435-43. PubMed ID: 19414797
[TBL] [Abstract][Full Text] [Related]
8. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
[TBL] [Abstract][Full Text] [Related]
9. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
[TBL] [Abstract][Full Text] [Related]
10. Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.
Courtney AN; Nehete PN; Nehete BP; Thapa P; Zhou D; Sastry KJ
Vaccine; 2009 May; 27(25-26):3335-41. PubMed ID: 19200849
[TBL] [Abstract][Full Text] [Related]
11. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
13. Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection.
Reilly EC; Thompson EA; Aspeslagh S; Wands JR; Elewaut D; Brossay L
PLoS One; 2012; 7(5):e37991. PubMed ID: 22649570
[TBL] [Abstract][Full Text] [Related]
14. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
[TBL] [Abstract][Full Text] [Related]
15. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
16. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
17. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor.
Cao Z; Yuan Y; Jeyabalan G; Du Q; Tsung A; Geller DA; Billiar TR
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G249-58. PubMed ID: 19556359
[TBL] [Abstract][Full Text] [Related]
18. Liposomal α-galactosylceramide is taken up by gut-associated lymphoid tissue and stimulates local and systemic immune responses.
Kaneko K; McDowell A; Ishii Y; Hook S
J Pharm Pharmacol; 2017 Dec; 69(12):1724-1735. PubMed ID: 28872688
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
[TBL] [Abstract][Full Text] [Related]
20. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
